<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4702357</article-id><article-id pub-id-type="publisher-id">1097</article-id><article-id pub-id-type="doi">10.1186/s13063-015-1097-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Ying</given-names></name><address><email>zhouying0129@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Feng</given-names></name><address><email>tianfeng301@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jing</given-names></name><address><email>wangjing121@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jun-Jie</given-names></name><address><email>fearlessly@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tao</given-names></name><address><email>zhangtao301@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jing</surname><given-names>Jing</given-names></name><address><email>jjing301@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Yun-Dai</given-names></name><address><phone>+86 10 55499009</phone><email>cyundai301@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853 China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>10</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>© Zhou et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary atherosclerosis. </plain></SENT>
<SENT sid="3" pm="."><plain>There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk. </plain></SENT>
<SENT sid="4" pm="."><plain>Coronary computed tomography angiography (CCTA) has emerged as a noninvasive imaging method for the analysis of coronary atherosclerosis and EAT volume. </plain></SENT>
<SENT sid="5" pm="."><plain>The purpose of this trial is to determine whether olmesartan medoxomil is effective at both treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="6" pm="."><plain>Methods/design </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>This study is a prospective, single-center, open-label, randomized controlled clinical trial aimed at exploring the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 194 patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly divided into olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). </plain></SENT>
<SENT sid="9" pm="."><plain>The primary outcome measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA at 12 months. </plain></SENT>
<SENT sid="10" pm="."><plain>The secondary outcome measures include the levels of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, TNF-α, matrix metalloproteinase 9, NO, endothelin 1, adiponectin, and leptin at baseline and after 6 and 12 months. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>Discussion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>Treatments aimed at reducing EAT volume can eventually achieve an antiatherosclerotic effect. </plain></SENT>
<SENT sid="13" pm="."><plain>This is the first trial designed to explore the effect of olmesartan medoxomil on both coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="14" pm="."><plain>Trial registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15" pm="."><plain>ClinicalTrials.gov: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02360956?term=NCT02360956&amp;rank=1">NCT02360956</ext-link>. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Coronary atherosclerosis</kwd><kwd>Coronary computed tomography angiography</kwd><kwd>Epicardial adipose tissue</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1" sec-type="introduction"><title><text><SENT sid="16" pm="."><plain>Background </plain></SENT>
</text></title><sec id="Sec2"><title><text><SENT sid="17" pm="."><plain>Epicardial adipose tissue and coronary atherosclerosis </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>Epicardial adipose tissue (EAT) is directly deposited around the pericardium and coronary artery. </plain></SENT>
<SENT sid="19" pm="."><plain>By autocrine and paracrine means, EAT can generate various kinds of cytokines, inflammatory mediators and free fatty acids. </plain></SENT>
<SENT sid="20" pm="."><plain>These biological indicators can affect the state of coronary endothelial function and promote inflammation and oxidative stress, which finally aggravate the progression of coronary atherosclerosis [1–3]. </plain></SENT>
<SENT sid="21" pm="."><plain>A significant amount of clinical research has been conducted to investigate the link between EAT and coronary atherosclerosis. </plain></SENT>
<SENT sid="22" pm="."><plain>It was claimed that calcified plaque progression in patients without coronary artery disease and in patients with type 2 diabetes mellitus were associated with a larger EAT volume [4, 5]. </plain></SENT>
<SENT sid="23" pm="."><plain>Epicardial adipose tissue is also an independent predictor of significant coronary stenosis and is independently associated with high-risk coronary plaque features, such as low CT attenuation plaque, thin-cap fibroatheroma and positive remodeling [6]. </plain></SENT>
<SENT sid="24" pm="."><plain>Not only is EAT, as a special visceral fat, correlated with the increased development of coronary artery atherosclerosis, but it is also associated with adverse coronary events [7]. </plain></SENT>
</text></p></sec><sec id="Sec3"><title><text><SENT sid="25" pm="."><plain>Treatment of epicardial adipose tissue and coronary atherosclerosis </plain></SENT>
</text></title><p><text><SENT sid="26" pm="."><plain>There are ample studies exploring the progression of coronary atherosclerosis following pharmacological manipulation. </plain></SENT>
<SENT sid="27" pm="."><plain>At the time of writing, the use of statins is recognized as an effective treatment; statins can result in decreases in plaque and necrotic core volume, and can also significantly reduce the progression of low attenuation plaque (&lt;30 Hounsfield units) and non-calcified plaque [8, 9]. </plain></SENT>
<SENT sid="28" pm="."><plain>Other drugs, such as dipeptidyl-peptidase 4 inhibitors [10], a PPARγ agonist (pioglitazone) [11], atorvastatin plus ezetimibe [12], olmesartan [13], have also been reported to have antiatherosclerotic effects, although the effects have not been verified by large-scale studies. </plain></SENT>
<SENT sid="29" pm="."><plain>As studies show that EAT volume is associated with plaque progression and cardiovascular adverse events, treatments aimed at reducing EAT volume may finally achieve an antiatherosclerotic, preventive effect. </plain></SENT>
<SENT sid="30" pm="."><plain>However, at the time of writing, limited studies have aimed at reducing both EAT and plaque volume to achieve an antiatherosclerotic effect. </plain></SENT>
<SENT sid="31" pm="."><plain>A serial coronary computed tomography angiography (CCTA) study recently indicated that intensive statin therapy can reduce the EAT volume of Europeans, but the study failed to demonstrate a relationship among EAT volume reduction, coronary atherosclerosis progression and clinical prognosis [14]; moreover, intensive statin therapy might not be appropriate for Asians. </plain></SENT>
<SENT sid="32" pm="."><plain>The epidemiological studies and clinical researches show that Asians may have poorer tolerability and safety to intensive statins than white people, owing to genetic differences (variants in structure or polymorphisms) in pharmacokinetics and pharmacodynamics properties [15–17]. </plain></SENT>
<SENT sid="33" pm="."><plain>It has been claimed that polymorphic variants in cytochrome P450 (CYP450) families that were associated with statin metabolism might result in varying rates of metabolic clearance. </plain></SENT>
<SENT sid="34" pm="."><plain>CYP450 2C19 slow metabolizer phenotype was reported to be present in approximately 16 % of Asians compared with only about 3 % of white people [18]. </plain></SENT>
<SENT sid="35" pm="."><plain>Polymorphic variants in the predominant CYP450 isoform, CYP450 3A4, were reported to be associated with a functional decrease in the enzyme’s activity in dyslipidemic Chinese patients [19]. </plain></SENT>
<SENT sid="36" pm="."><plain>The HPS2-THRIVE study recently also indicated that, using same-dose statin treatment, an excess of increased alanine aminotransferase was seen mainly among Chinese patients (more than three consecutive values above the upper limit of normal of 0.24 %/year compared with 0.02 %/year in Europe) [20]. </plain></SENT>
<SENT sid="37" pm="."><plain>Moreover, the morbidity of chronic hepatitis B was high in china with nearly 90 million infections. </plain></SENT>
<SENT sid="38" pm="."><plain>For these reasons, intensive statin therapy may result in higher hepatotoxicity in Asian populations than in white populations, so low- to moderate- dose statin therapy might be more appropriate for Asian populations [15, 16]. </plain></SENT>
<SENT sid="39" pm="."><plain>Subjects who undergo weight loss exercise, bariatric surgery, or low-dose aspirin therapy can also reduce EAT volume or inflammation, but the effects are weak and these treatments cannot achieve good results in patients with coronary atherosclerosis progression [21–24]. </plain></SENT>
<SENT sid="40" pm="."><plain>Our aim is to find a drug that reduces EAT volume while inhibiting the progression of coronary atherosclerosis. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>In recent years, studies have confirmed that olmesartan medoxomil can improve endothelial function, resist thrombosis, improve tissue reconstruction, and resist oxidative stress to achieve atherosclerosis resistance [13, 25–28]. </plain></SENT>
<SENT sid="42" pm="."><plain>The latest research shows that olmesartan medoxomil can better inhibit rat epididymal adipose cell hypertrophy and inflammatory reactions [29]. </plain></SENT>
<SENT sid="43" pm="."><plain>Therefore, we hypothesized that olmesartan medoxomil may also reduce EAT volume, finally achieving an anti-atherosclerosis effect. </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="44" pm="."><plain>EAT and coronary atherosclerosis imaging with computed tomography </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>Compared with such invasive methods as intravascular ultrasound, virtual histology intravascular ultrasound, optical coherence tomography, and fractional flow reserve, CCTA has emerged as a noninvasive imaging method that analyzes both coronary atherosclerosis and EAT volume [14, 30]. </plain></SENT>
<SENT sid="46" pm="."><plain>To date, ample CCTA studies have explored the progression of coronary atherosclerosis following pharmacological manipulation. </plain></SENT>
<SENT sid="47" pm="."><plain>Thus, in this study, using CCTA as a noninvasive method to analyze both coronary atherosclerosis progression and EAT volume is of significant clinical value. </plain></SENT>
</text></p><sec id="Sec5"><title><text><SENT sid="48" pm="."><plain>Aims of the main study </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>The purpose of this study is to determine whether olmesartan medoxomil is effective on both the treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="50" pm="."><plain>Aims of the anti-atherosclerosis mechanism study </plain></SENT>
</text></title><p><text><SENT sid="51" pm="."><plain>To explore the relationship between coronary atherosclerosis progression and EAT volume reduction.To explore the effect of olmesartan medoxomil on serum levels of blood lipids, glucose, circulating surrogate markers of atherosclerosis inflammation, including high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1 (MCP-1), TNF-α, and matrix metalloproteinase 9 (MMP-9), circulating surrogate markers of endothelial function, including NO and endothelin 1 (ET-1), and circulating surrogate markers of adipose tissue inflammation and metabolism, including adiponectin and leptin at baseline and after 6 and 12 months. </plain></SENT>
</text></p></sec></sec></sec></SecTag><SecTag type="METHODS"><sec id="Sec7" sec-type="materials|methods"><title><text><SENT sid="52" pm="."><plain>Methods/design </plain></SENT>
</text></title><sec id="Sec8"><title><text><SENT sid="53" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="54" pm="."><plain>This study is a prospective, single-center (Chinese PLA General Hospital, Beijing, China), open-label, randomized controlled trial of the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. </plain></SENT>
<SENT sid="55" pm="."><plain>Consecutive patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly assigned to olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). </plain></SENT>
<SENT sid="56" pm="."><plain>Coronary computed tomography angiography will be conducted at the Department of Cardiology (Chinese PLA General Hospital). </plain></SENT>
<SENT sid="57" pm="."><plain>Primary outcome measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA, at 12 months. </plain></SENT>
<SENT sid="58" pm="."><plain>Secondary outcome measures include levels of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, MCP-1, TNF-α, MMP-9, NO, ET-1, adiponectin, and leptin at baseline and after 6 and 12 months. </plain></SENT>
<SENT sid="59" pm="."><plain>The study design is summarized in Fig. 1.Fig. 1Study flowchart. </plain></SENT>
<SENT sid="60" pm="."><plain>CCTA, coronary computed tomography angiography; DBP, diastolic blood pressure; EAT, epicardial adipose tissue; SBP, systolic blood pressure </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="61" pm="."><plain>Clinical inclusion and exclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>Clinical inclusion criteria are:Age between 18 and 75 years;Coronary artery stenosis between 30 % and 70 % determined by CCTA in essential hypertension patients;Resting diastolic blood pressure between 90 and 110 mmHg;Type A and B for coronary artery vascular lesions. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>Clinical exclusion criteria are:Secondary hypertension;Coronary artery stenosis less than 30 % or greater than 70 %, as determined by CCTA;Severe arrhythmia;Severe cardiac insufficiency or left ventricular dysfunction (left ventricular ejection fraction &lt; 30 %);Severe hepatic or kidney insufficiency;Resting systolic blood pressure &gt; 200 mmHg or resting diastolic blood pressure &gt;110 mmHg;Contraindications to treatment with olmesartan medoxomil (allergy, glaucoma, digestive ulcer, currently taking phosphodiesterase-5 inhibitor);Severe calcification, distortion or type C coronary artery vascular lesions;Pregnancy;Unwillingness or inability to provide informed consent. </plain></SENT>
</text></p></sec><sec id="Sec10"><title><text><SENT sid="64" pm="."><plain>Randomization </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Information regarding the study will be provided to the patient at the Department of Cardiology. </plain></SENT>
<SENT sid="66" pm="."><plain>Once informed consent is obtained, the patient will be randomized at the Department of Cardiology. </plain></SENT>
<SENT sid="67" pm="."><plain>Subjects will be randomized to either olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). </plain></SENT>
<SENT sid="68" pm="."><plain>Participants will be randomized before the first treatment using a blocked randomization procedure (computerized random numbers) and will incorporate minimization to ensure matching for age, sex, body mass index, and hypertension grade. </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="69" pm="."><plain>Ethical considerations </plain></SENT>
</text></title><p><text><SENT sid="70" pm="."><plain>The Chinese PLA General Hospital Ethics Committee approved this study on 12 December 2014 (reference number S2014-119-01). </plain></SENT>
<SENT sid="71" pm="."><plain>This study complies with the Declaration of Helsinki. </plain></SENT>
<SENT sid="72" pm="."><plain>Informed consent will be obtained from all participating patients. </plain></SENT>
<SENT sid="73" pm="."><plain>Upon signing informed consent, patients’ data will be populated as per protocol. </plain></SENT>
</text></p></sec><sec id="Sec12"><title><text><SENT sid="74" pm="."><plain>Details of CCTA examination </plain></SENT>
</text></title><sec id="Sec13"><title><text><SENT sid="75" pm="."><plain>CCTA examination procedure </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>CCTA will be performed on a dual-source CT scanner (Somatom Definition Flash, Siemens Healthcare, Forchheim, Germany). </plain></SENT>
<SENT sid="77" pm="."><plain>All enrolled patients will be instructed in the breath-holding technique before CCTA to minimize breathing artifacts. </plain></SENT>
<SENT sid="78" pm="."><plain>Three minutes before CCTA, all patients will be given 0.5 mg nitroglycerin sublingually to dilate the coronary artery. </plain></SENT>
<SENT sid="79" pm="."><plain>The scan range is from the carina or the pulmonary artery segment down to 1 cm below the diaphragm. </plain></SENT>
<SENT sid="80" pm="."><plain>Electrocardiography is continuously performed throughout the entire examination for each patient. </plain></SENT>
<SENT sid="81" pm="."><plain>A dual-head power injector (SCT 210, Medrad, USA) and a nonionic contrast medium (Ultravist®, 370 mg I /ml, Schering AG, Guangzhou, China) will be used. </plain></SENT>
<SENT sid="82" pm="."><plain>The collimation is 2 × 128 × 0.6 mm, the gantry rotation time is 0.28 ms, the slice thickness is 0.6 mm, the tube voltage is 80 to 120 kV (modified using a care kV, Siemens Medical Solutions, Forchheim, Germany), and the tube current is 290 to 560 mAs/rotation (scout-based automatic reference tube current selection – CareDose 4D, Siemens Medical Solutions, Forchheim, Germany). </plain></SENT>
<SENT sid="83" pm="."><plain>For double flash acquisition, the pitch is 3.4, and for retrospectively ECG-triggered spiral acquisition, the pitch will vary depending on the patient’s heart rate. </plain></SENT>
<SENT sid="84" pm="."><plain>Total estimated radiation dose for the patient will be recorded. </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>Patients with a heart rate ≤70 beats/min will be evaluated using double prospective ECG-gated high-pitch CT angiography (double flash mode). </plain></SENT>
<SENT sid="86" pm="."><plain>For the double flash protocol, the contrast-enhanced CCTA protocol is as follows: a test bolus scan will be performed at the level of the aortic root with administration of 15 ml of contrast medium into the right antecubital vein at a rate of 5.0 ml/s, followed by an injection of 20 ml of saline flush at the same flow rate to obtain a peak enhancement time curve. </plain></SENT>
<SENT sid="87" pm="."><plain>The double flash acquisition triggered scan time is 4 s after the peak enhancement time. </plain></SENT>
<SENT sid="88" pm="."><plain>After calculating the triggered scan time, double flash acquisition will be performed by injecting 60 to 90 ml contrast medium at a rate of 5.0 ml/s, immediately followed by 35 ml of 70/30 contrast/saline material mixture and 50 ml saline bolus at the same flow rate. </plain></SENT>
<SENT sid="89" pm="."><plain>The first scan will begin at 60 % of the R-R interval from the craniocaudal direction. </plain></SENT>
<SENT sid="90" pm="."><plain>The second scan will be acquired at 30 % of the R-R interval 3 s after the first scan during the same contrast injection time. </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>Patients with a heart rate &gt;70 beats/min will be evaluated using retrospectively ECG-triggered spiral acquisition. </plain></SENT>
<SENT sid="92" pm="."><plain>The retrospective protocol is as follows: 60 to 90 ml contrast medium is injected into the antecubital vein at a rate of 5.0 ml/s, immediately followed by 50 ml saline solution at the same flow rate. </plain></SENT>
<SENT sid="93" pm="."><plain>Bolus tracking is used, and the region of interest is set at the root of the ascending aorta. </plain></SENT>
<SENT sid="94" pm="."><plain>We will perform the scan with a delay of 5 s after the root of the ascending aorta reaches a threshold of 100 Hounsfield units. </plain></SENT>
<SENT sid="95" pm="."><plain>For this scan mode, the acquisition is from 30 % to 80 % of the R-R interval. </plain></SENT>
</text></p></sec><sec id="Sec14"><title><text><SENT sid="96" pm="."><plain>CCTA image post-processing </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>All CCTA data will be sent to the Syngo Multi-Modality Workplace for post-processing. </plain></SENT>
<SENT sid="98" pm="."><plain>Two independent experienced observers who are unaware of the patients’ clinical information will evaluate the CCTA data in different modes, including maximum intensity projection, volume rendering, curved-planar reconstructions, and the original transaxial images. </plain></SENT>
<SENT sid="99" pm="."><plain>Disagreements in data analysis between the two readers will be resolved by consensus reading. </plain></SENT>
</text></p></sec><sec id="Sec15"><title><text><SENT sid="100" pm="."><plain>Epicardial adipose tissue quantification </plain></SENT>
</text></title><p><text><SENT sid="101" pm="."><plain>The EAT volume will be measured by two experienced radiologists using the same sets of images acquired for the CCTA. </plain></SENT>
<SENT sid="102" pm="."><plain>The radiologists will be blinded to the purpose of the study, clinical characteristics and patients’ anthropometric data. </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>The EAT volume is defined as the total amount of adipose tissue deposited between the surface of the heart and the visceral pericardium. </plain></SENT>
<SENT sid="104" pm="."><plain>The region of interest in measuring the EAT volume includes the heart and the surrounding EAT. </plain></SENT>
<SENT sid="105" pm="."><plain>By manually tracing the epicardium contours in the axial slices from the bifurcation of the pulmonary artery to the diaphragm, the EAT volume is analyzed. </plain></SENT>
<SENT sid="106" pm="."><plain>The pericardium contour is traced every 10 mm, from the lower visible level of the pulmonary artery bifurcation until the top level of the pulmonary valve, for every 20 mm until the first slice where the diaphragm becomes visible, and for every 10 mm from this point until the last slice where the pericardium is still visible [31]. </plain></SENT>
<SENT sid="107" pm="."><plain>The pericardium contour is manually outlined by the radiologists, and then the software (Syngo Volume, Siemens Medical Solutions) automatically calculates the total EAT volume. </plain></SENT>
<SENT sid="108" pm="."><plain>Computed tomography attenuation ranging from −195 to 45 Hounsfield units is applied to isolate the EAT from other tissues. </plain></SENT>
<SENT sid="109" pm="."><plain>Mediastinal adipose tissue and pericardial adipose fat (fat deposit outside the visceral pericardium and on the external surface of the parietal pericardium) are excluded from the analysis. </plain></SENT>
<SENT sid="110" pm="."><plain>For the assessment of interobserver agreement, we will randomly select 50 patients, and all EAT measures will be assessed by two experienced radiologists blinded to the other radiologist’s measurements. </plain></SENT>
</text></p></sec><sec id="Sec16"><title><text><SENT sid="111" pm="."><plain>Definition of coronary atherosclerosis plaque progression </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>We will use QAngio CT post-processing software (QAngioCT Research Edition version 2.1.0, Medis Medical Imaging Systems, Leiden, the Netherlands) to evaluate all CCTA data. </plain></SENT>
<SENT sid="113" pm="."><plain>All three vessels will be assessed in each patient using the 15-segment American Heart Association model for coronary segment classification [32]. </plain></SENT>
<SENT sid="114" pm="."><plain>Only segments with a diameter ≥2.0 mm and without stent implantation will be considered for analysis. </plain></SENT>
<SENT sid="115" pm="."><plain>Parameters including minimal lumen diameter, percent diameter stenosis, minimum lumen area, plaque burden, plaque volume, vascular remodeling index, plaque type classification (calcification, necrosis, fiber, and fiber lipid plaques) based on segments will be analyzed using QAngio CT post-processing software. </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>Coronary atherosclerosis progression is defined as ≥10 % diameter reduction or progression of a pre-existing coronary stenosis or ≥0.2 mm reduction or progression of the minimal luminal diameter in the lesion [30]. </plain></SENT>
</text></p></sec></sec><sec id="Sec17"><title><text><SENT sid="117" pm="."><plain>Medication intervention and control protocols </plain></SENT>
</text></title><p><text><SENT sid="118" pm="."><plain>All patients should accept lifestyle interventions and conventional anti-atherosclerosis treatment. </plain></SENT>
<SENT sid="119" pm="."><plain>The low-density lipoprotein cholesterol level should be controlled below 100 mg/dl, and the blood pressure should be controlled below 140/90 mmHg. </plain></SENT>
</text></p><p><text><SENT sid="120" pm="."><plain>In the olmesartan medoxomil group, the usual recommended starting dose of olmesartan medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. </plain></SENT>
<SENT sid="121" pm="."><plain>For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of olmesartan medoxomil may be increased to 40 mg. </plain></SENT>
<SENT sid="122" pm="."><plain>Doses above 40 mg do not appear to have a greater effect. </plain></SENT>
<SENT sid="123" pm="."><plain>Twice-daily dosing offers no advantage over the same total dose given once daily. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>In the control group, any antihypertensive medication alone or in combination, including calcium channel blockers, diuretics, beta blockers, or other antihypertensive medication except angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers can be used. </plain></SENT>
<SENT sid="125" pm="."><plain>The drug dose must be individualized. </plain></SENT>
<SENT sid="126" pm="."><plain>The patients should take the antihypertensive drugs according to the doctors’ recommendations. </plain></SENT>
</text></p></sec><sec id="Sec18"><title><text><SENT sid="127" pm="."><plain>Study outcomes </plain></SENT>
</text></title><p><text><SENT sid="128" pm="."><plain>The primary outcome measures are coronary atherosclerosis progression and EAT volume changes, as detected by CCTA at 12 months. </plain></SENT>
</text></p><p><text><SENT sid="129" pm="."><plain>The secondary outcome measures includeThe relationship between coronary atherosclerosis and EAT;Serum levels of blood lipids, glucose, circulating surrogate markers of atherosclerotic inflammation including high-sensitivity C-reactive protein, IL-6, MCP-1, TNF-α, and MMP-9, individual circulating surrogate markers of endothelial function including NO and ET-1, and individual circulating surrogate markers of adipose tissue inflammation and metabolism including adiponectin and leptin at baseline and after 6 and 12 months. </plain></SENT>
</text></p></sec><sec id="Sec19"><title><text><SENT sid="130" pm="."><plain>Biomarkers </plain></SENT>
</text></title><p><text><SENT sid="131" pm="."><plain>Two 10-ml samples of blood will be collected from the antecubital vein by a trained nurse for each individual. </plain></SENT>
<SENT sid="132" pm="."><plain>Fasting blood samples will be obtained between 7:00 a.m. and 12:00 noon to control for possible diurnal variations. </plain></SENT>
<SENT sid="133" pm="."><plain>Blood samples will be centrifuged at 4 °C and 3,000 rpm for 15 min. </plain></SENT>
<SENT sid="134" pm="."><plain>The serum will be sampled and stored at −80 °C until analysis. </plain></SENT>
<SENT sid="135" pm="."><plain>Traditional cardiovascular blood risk markers, including fasting blood glucose, triglycerides, total cholesterol, and high- and low-density lipoprotein cholesterol will be assessed. </plain></SENT>
<SENT sid="136" pm="."><plain>The following proinflammatory markers will be assessed: high-sensitivity C-reactive protein, IL-6, TNF-α, MCP-1, and MMP-9. </plain></SENT>
<SENT sid="137" pm="."><plain>In addition, NO and ET-1 will be measured, to assess endothelial function. </plain></SENT>
<SENT sid="138" pm="."><plain>Markers of adipose tissue inflammation and metabolism, including adiponectin and leptin, will also be assessed. </plain></SENT>
<SENT sid="139" pm="."><plain>These markers will be measured at baseline and 6 and 12 months after treatment. </plain></SENT>
</text></p></sec><sec id="Sec20"><title><text><SENT sid="140" pm="."><plain>Follow-up </plain></SENT>
</text></title><p><text><SENT sid="141" pm="."><plain>Clinical follow-up will take place at 1 month (±1 week), 3 months (±2 weeks), 6 months (±2 weeks), 9 months (±30 days), and 1 year (±30 days) by clinical visit or phone interview. </plain></SENT>
</text></p><p><text><SENT sid="142" pm="."><plain>At baseline and 6-month (±2 weeks) and 1 year (±30 days) follow-ups, all patients will provide venous blood for detection of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, MCP-1, TNF-α, NO, ET-1, MMP-9, adiponectin, and leptin. </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>At 1 year (±30 days) follow-up, all patients will undergo CCTA (with QAngio CT post-processing software).We anticipated a patient drop-out rate of 10 %. </plain></SENT>
</text></p></sec><sec id="Sec21"><title><text><SENT sid="144" pm="."><plain>Sample size calculation </plain></SENT>
</text></title><p><text><SENT sid="145" pm="."><plain>This trial is an open-label randomized clinical trial, so patients will randomly be assigned to olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). </plain></SENT>
<SENT sid="146" pm="."><plain>The purpose of this study is to verify that olmesartan medoxomil is effective in the treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. </plain></SENT>
<SENT sid="147" pm="."><plain>We also want to elucidate the relationship between coronary atherosclerosis and EAT. </plain></SENT>
<SENT sid="148" pm="."><plain>The mechanism by which olmesartan medoxomil inhibits coronary atherosclerosis progression will be studied by detecting the serum levels of blood lipids, glucose, circulating surrogate markers of atherosclerosis inflammation including high-sensitivity C-reactive protein, IL-6, MCP-1, TNF-α, and MMP-9, circulating surrogate markers of endothelial function, including NO and ET-1, and circulating surrogate markers of adipose tissue inflammation and metabolism, including adiponectin and leptin. </plain></SENT>
</text></p><p><text><SENT sid="149" pm="."><plain>Studies on coronary atherosclerosis progression rate have had differing results. </plain></SENT>
<SENT sid="150" pm="."><plain>The combined results of multiple studies indicate that the conventional mean coronary atherosclerosis progression rate is about 30 % [33–35]. </plain></SENT>
<SENT sid="151" pm="."><plain>We hypothesize that additional olmesartan medoxomil use will reduce the coronary atherosclerosis progression rate to 13 % [36–40]. </plain></SENT>
<SENT sid="152" pm="."><plain>Using double-side inspection, α = 0.05, β = 0.2, we calculate a total sample size of 176 cases; considering the expected loss to follow-up to be 10 %, the number of cases to be included should be at least 176 × (1 + 10 %) = 194. </plain></SENT>
<SENT sid="153" pm="."><plain>Therefore, we aim for 97 cases of each group. </plain></SENT>
</text></p></sec><sec id="Sec22"><title><text><SENT sid="154" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>Continuous variables will be described using means and standard deviations or median and range in case of asymmetric distribution of data. </plain></SENT>
<SENT sid="156" pm="."><plain>Categorical variables will be presented using frequency distribution. </plain></SENT>
<SENT sid="157" pm="."><plain>Univariate analyses will be conducted using chi-square and t tests for independent samples. </plain></SENT>
<SENT sid="158" pm="."><plain>A multiple logistic regression analysis will be performed to correlate coronary atherosclerosis progression with clinical variables and EAT volume, including treatment groups. </plain></SENT>
<SENT sid="159" pm="."><plain>Statistical significance will be considered for P &lt; 0.05. </plain></SENT>
<SENT sid="160" pm="."><plain>A statistical package (SPSS 16.0) will be used for analysis. </plain></SENT>
<SENT sid="161" pm="."><plain>The individual will be considered the unit of analysis. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec23" sec-type="discussion"><title><text><SENT sid="162" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="163" pm="."><plain>To date, there are ample CCTA studies exploring the progression of coronary atherosclerosis following pharmacological manipulation. </plain></SENT>
<SENT sid="164" pm="."><plain>As studies show that EAT volume is associated with plaque progression and cardiovascular adverse events, treatments aimed at reducing EAT volume may finally achieve an antiatherosclerotic, preventive effect. </plain></SENT>
<SENT sid="165" pm="."><plain>However, at the time of writing, only a limited number of studies have aimed to reduce both EAT and plaque volume to achieve a preventive effect against atherosclerosis. </plain></SENT>
<SENT sid="166" pm="."><plain>The novelty of this study is that we intend to explore the effect of olmesartan medoxomil on both plaque volume and epicardial fat. </plain></SENT>
<SENT sid="167" pm="."><plain>This study will accomplish two goals: (1) it will explain the relationship between EAT volume and coronary atherosclerosis progression and (2) it will verify the effect of olmesartan medoxomil on EAT volume reduction and coronary atherosclerosis progression. </plain></SENT>
</text></p><p><text><SENT sid="168" pm="."><plain>If these hypotheses are supported, the study findings will have significant implications related to clinical practice. </plain></SENT>
<SENT sid="169" pm="."><plain>Evidence that olmesartan medoxomil is effective on EAT volume reduction and coronary atherosclerosis progression would be very attractive to clinicians and patients. </plain></SENT>
<SENT sid="170" pm="."><plain>This may further contribute to the care of patients with coronary heart disease. </plain></SENT>
</text></p></sec></SecTag><sec id="Sec24"><title><text><SENT sid="171" pm="."><plain>Trial status </plain></SENT>
</text></title><p><text><SENT sid="172" pm="."><plain>Recruitment for the study is currently ongoing. </plain></SENT>
<SENT sid="173" pm="."><plain>Patient recruitment began in December 2014. </plain></SENT>
</text></p></sec></body><back><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>CCTA</term><def><p>coronary computed tomography angiography</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>CYP450</term><def><p>cytochrome P450</p></def></def-item><def-item><term>EAT</term><def><p>epicardial adipose tissue</p></def></def-item><def-item><term>ET-1</term><def><p>endothelin 1</p></def></def-item><def-item><term>IL-6</term><def><p>interleukin 6</p></def></def-item><def-item><term>MCP-1</term><def><p>monocyte chemotactic protein 1</p></def></def-item><def-item><term>MMP-9</term><def><p>matrix metalloproteinase 9</p></def></def-item><def-item><term>TNF-α</term><def><p>tumor necrosis factor α</p></def></def-item></def-list></glossary></SecTag><fn-group><fn><p><text><SENT sid="174" pm="."><plain>Competing interests </plain></SENT>
</text></p><p><text><SENT sid="175" pm="."><plain>The authors declare no competing interests. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="176" pm="."><plain>Authors’ contributions </plain></SENT>
</text></p><p><text><SENT sid="177" pm="."><plain>YZ conceived the study and drafted this manuscript, and will also conduct the CCTA examinations and image analysis. </plain></SENT>
<SENT sid="178" pm="."><plain>FT and JJ will conduct patient recruitment. </plain></SENT>
<SENT sid="179" pm="."><plain>JJY will conduct the CCTA examinations and image analysis. </plain></SENT>
<SENT sid="180" pm="."><plain>JW and TZ performed the statistical analysis and helped to draft this manuscript. </plain></SENT>
<SENT sid="181" pm="."><plain>YDC is the Head of the Department of Cardiology, conceived the study, and drafted this manuscript. </plain></SENT>
<SENT sid="182" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="183" pm="."><plain>We are grateful to numerous colleagues who are providing clinical and research support in treating and following the patients included in this trial. </plain></SENT>
<SENT sid="184" pm="."><plain>This work was confirmed as Scientific Innovation Research supported by Chinese PLA General Hospital. </plain></SENT>
<SENT sid="185" pm="."><plain>The funding body had no role in designing the study, nor will it be involved in the collection, analysis, or interpretation of data. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="186" pm="."><plain>1.IacobellisGCorradiDSharmaAMEpicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heartNat Clin Pract Cardiovasc Med20052105364310.1038/ncpcardio0319<?supplied-pmid 16186852?>16186852 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="187" pm="."><plain>2.IacobellisGBiancoACEpicardial adipose tissue: emerging physiological, pathophysiological and clinical featuresTrends Endocrinol Metab20112211450710.1016/j.tem.2011.07.003<?supplied-pmid 21852149?>21852149 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="188" pm="."><plain>3.SacksHSFainJNHuman epicardial adipose tissue: a reviewAm Heart J200715369071710.1016/j.ahj.2007.03.019<?supplied-pmid 17540190?>17540190 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="189" pm="."><plain>4.RositoGAMassaroJMHoffmannURubergFLMahabadiAAVasanRSPericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart StudyCirculation200811756051310.1161/CIRCULATIONAHA.107.743062<?supplied-pmid 18212276?>18212276 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="190" pm="."><plain>5.YerramasuADeyDVenurajuSAnandDVAtwalSCorderRIncreased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosisAtherosclerosis201222012233010.1016/j.atherosclerosis.2011.09.041<?supplied-pmid 22015177?>22015177 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="191" pm="."><plain>6.RajaniRShmilovichHNakazatoRNakanishiROtakiYChengVYRelationship of epicardial fat volume to coronary plaque, severe coronary stenosis, and high-risk coronary plaque features assessed by coronary CT angiographyJ Cardiovasc Comput Tomogr2013721253210.1016/j.jcct.2013.02.003<?supplied-pmid 23622507?>23622507 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="192" pm="."><plain>7.MahabadiAABergMHLehmannNKalschHBauerMKaraKAssociation of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall StudyJ Am Coll Cardiol2013611313889510.1016/j.jacc.2012.11.062<?supplied-pmid 23433560?>23433560 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="193" pm="."><plain>8.InoueKMotoyamaSSaraiMSatoTHarigayaHHaraTSerial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin interventionJACC Cardiovasc Imaging201037691810.1016/j.jcmg.2010.04.011<?supplied-pmid 20633846?>20633846 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="194" pm="."><plain>9.ZebILiDNasirKMalpesoJBatoolAFloresFEffect of statin treatment on coronary plaque progression – a serial coronary CT angiography studyAtherosclerosis2013231219820410.1016/j.atherosclerosis.2013.08.019<?supplied-pmid 24267226?>24267226 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="195" pm="."><plain>10.ShahZKampfrathTDeiuliisJAZhongJPinedaCYingZLong-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxisCirculation20111242123384910.1161/CIRCULATIONAHA.111.041418<?supplied-pmid 22007077?>22007077 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="196" pm="."><plain>11.ManiPUnoKSt JohnJKupferSPerezATuzcuEMFavorable impact on LDL particle size in response to treatment with pioglitazone is associated with less progression of coronary atherosclerosis in patients with type 2 diabetesJ Am Coll Cardiol2015663328910.1016/j.jacc.2015.05.023<?supplied-pmid 26184626?>26184626 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="197" pm="."><plain>12.TsujitaKSugiyamaSSumidaHShimomuraHYamashitaTYamanagaKImpact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trialJ Am Coll Cardiol201566549550710.1016/j.jacc.2015.05.065<?supplied-pmid 26227186?>26227186 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="198" pm="."><plain>13.HirohataAYamamotoKMiyoshiTHatanakaKHirohataSYamawakiHImpact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trialJ Am Coll Cardiol201055109768210.1016/j.jacc.2009.09.062<?supplied-pmid 20202514?>20202514 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="199" pm="."><plain>14.AlexopoulosNMelekBHArepalliCDHartlageGRChenZKimSEffect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (beyond endorsed lipid lowering with EBT scanning)J Am Coll Cardiol2013611919566110.1016/j.jacc.2012.12.051<?supplied-pmid 23500254?>23500254 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="200" pm="."><plain>15.Expert Panel of 2014 China Cholesterol Education Program Experts Recommendations for Management of Dyslipidemia, Working Group on Blood Lipid and Atherosclerosis of Editorial Board of Chinese Journal of Cardiology, Epidemiology Group of Chinese Society of Cardiology, Expert Panel of 2014 China Cholesterol Education Program Experts Recommendations for Management of Dyslipidemia, Working Group on Blood Lipid and Atherosclerosis of Editorial Board of Chinese Journal of Cardiology, Epidemiology Group of Chinese Society of Cardiology. </plain></SENT>
<SENT sid="201" pm="."><plain>2014 China cholesterol education program experts recommendations on management of dyslipidemia. </plain></SENT>
<SENT sid="202" pm="."><plain>Zhonghua Xin Xue Guan Bing Za Zhi. </plain></SENT>
<SENT sid="203" pm="."><plain>2014; 42(8):633–6. </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="204" pm="."><plain>16.StoneNJRobinsonJGLichtensteinAHBairey MerzCNBlumCBEckelRH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20146325 Pt B288993410.1016/j.jacc.2013.11.002<?supplied-pmid 24239923?>24239923 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="205" pm="."><plain>17.LiaoJKSafety and efficacy of statins in AsiansAm J Cardiol2007993410410.1016/j.amjcard.2006.08.051<?supplied-pmid 17261409?>17261409 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="206" pm="."><plain>18.PoolsupNLi Wan PoAKnightTLPharmacogenetics and psychopharmacotherapyJ Clin Pharm Ther200025319722010.1046/j.1365-2710.2000.00281.x<?supplied-pmid 10886465?>10886465 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="207" pm="."><plain>19.WangAYuBNLuoCHTanZRZhouGWangLSIle118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patientsEur J Clin Pharmacol20056012843810.1007/s00228-004-0848-7<?supplied-pmid 15650881?>15650881 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="208" pm="."><plain>20.HPS2-THRIVERandomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J.2013341712799110.1093/eurheartj/eht05523444397 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="209" pm="."><plain>21.KimMKTomitaTKimMJSasaiHMaedaSTanakaKAerobic exercise training reduces epicardial fat in obese menJ Appl Physiol (1985)2009106151110.1152/japplphysiol.90756.200818927266 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="210" pm="."><plain>22.IacobellisGSinghNWhartonSSharmaAMSubstantial changes in epicardial fat thickness after weight loss in severely obese subjectsObesity (Silver Spring).20081671693710.1038/oby.2008.251<?supplied-pmid 18451775?>18451775 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="211" pm="."><plain>23.WillensHJByersPChirinosJALabradorEHareJMde MarchenaEEffects of weight loss after bariatric surgery on epicardial fat measured using echocardiographyAm J Cardiol20079991242510.1016/j.amjcard.2006.12.042<?supplied-pmid 17478151?>17478151 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="212" pm="."><plain>24.GrossoAFde OliveiraSFHiguchi MdeLFavaratoDDallanLAda LuzPLSynergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndromeDiabetol Metab Syndr2014614710.1186/1758-5996-6-47<?supplied-pmid 24684779?>24684779 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="213" pm="."><plain>25.MiyoshiTHirohataAUsuiSYamamotoKMurakamiTKomatsubaraIOlmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trialHeart Vessels20142921788510.1007/s00380-013-0343-0<?supplied-pmid 23563752?>23563752 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="214" pm="."><plain>26.MasonRPOptimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomilVasc Health Risk Manag.201174051610.2147/VHRM.S20737<?supplied-pmid 21796255?>21796255 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="215" pm="."><plain>27.FerrarioCEffect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomilVasc Health Risk Manag2009513011410.2147/VHRM.S3141<?supplied-pmid 19436655?>19436655 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="216" pm="."><plain>28.FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation200411091103710.1161/01.CIR.0000140265.21608.8E<?supplied-pmid 15313950?>15313950 </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="217" pm="."><plain>29.MaedaATamuraKWakuiHOhsawaMAzushimaKUnedaKEffects of the angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disordersBioMed Res Int.2014201494649210.1155/2014/946492<?supplied-pmid 24991574?>24991574 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="218" pm="."><plain>30.BoogersMJSchuijfJDKitslaarPHvan WerkhovenJMde GraafFRBoersmaEAutomated quantification of stenosis severity on 64-slice CT: a comparison with quantitative coronary angiographyJACC Cardiovasc Imaging20103769970910.1016/j.jcmg.2010.01.010<?supplied-pmid 20633847?>20633847 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="219" pm="."><plain>31.BettencourtNToschkeAMLeiteDRochaJCarvalhoMSampaioFEpicardial adipose tissue is an independent predictor of coronary atherosclerotic burdenInt J Cardiol20121581263210.1016/j.ijcard.2010.12.085<?supplied-pmid 21255849?>21255849 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="220" pm="."><plain>32.AustenWGEdwardsJEFryeRLGensiniGGGottVLGriffithLSA reporting system on patients evaluated for coronary artery disease. </plain></SENT>
<SENT sid="221" pm="."><plain>Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart AssociationCirculation1975514 Suppl54010.1161/01.CIR.51.4.5<?supplied-pmid 1116248?>1116248 </plain></SENT>
</text></ref><ref id="CR33"><text><SENT sid="222" pm="."><plain>33.ZhengJLLuLHuJZhangRYZhangQChenQJIncreased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery diseaseAtherosclerosis20102102590510.1016/j.atherosclerosis.2009.12.016<?supplied-pmid 20056225?>20056225 </plain></SENT>
</text></ref><ref id="CR34"><text><SENT sid="223" pm="."><plain>34.HanYJingJTuSTianFXueHChenWST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosisInt J Cardiovasc Imaging20143022536110.1007/s10554-013-0354-z<?supplied-pmid 24420418?>24420418 </plain></SENT>
</text></ref><ref id="CR35"><text><SENT sid="224" pm="."><plain>35.BourantasCVGarcia-GarciaHMFarooqVMaeharaAXuKGenereuxPClinical and angiographic characteristics of patients likely to have vulnerable plaques: analysis from the PROSPECT studyJACC Cardiovasc Imaging201361212637210.1016/j.jcmg.2013.04.015<?supplied-pmid 24269259?>24269259 </plain></SENT>
</text></ref><ref id="CR36"><text><SENT sid="225" pm="."><plain>36.PuriRNissenSEShaoMBallantyneCMBarterPJChapmanMJCoronary atheroma volume and cardiovascular events during maximally intensive statin therapyEur Heart J2013344131829010.1093/eurheartj/eht260<?supplied-pmid 23886915?>23886915 </plain></SENT>
</text></ref><ref id="CR37"><text><SENT sid="226" pm="."><plain>37.PuriRNissenSELibbyPShaoMBallantyneCMBarterPJC-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapyCirculation201312822239540310.1161/CIRCULATIONAHA.113.004243<?supplied-pmid 24043299?>24043299 </plain></SENT>
</text></ref><ref id="CR38"><text><SENT sid="227" pm="."><plain>38.NichollsSJBallantyneCMBarterPJChapmanMJErbelRMLibbyPEffect of two intensive statin regimens on progression of coronary diseaseN Engl J Med20113652220788710.1056/NEJMoa1110874<?supplied-pmid 22085316?>22085316 </plain></SENT>
</text></ref><ref id="CR39"><text><SENT sid="228" pm="."><plain>39.ChristophMHeroldJBerg-HolldackARauwolfTZiemssenTSchmeisserAEffects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trialHeart Vessels20153032869510.1007/s00380-014-0480-0<?supplied-pmid 24519403?>24519403 </plain></SENT>
</text></ref><ref id="CR40"><text><SENT sid="229" pm="."><plain>40.ClementiFDi LuozzoMMangoRLucianiGTrivisonnoAPizzutoFRegression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysisJ Cardiovasc Med (Hagerstown)2009103231710.2459/JCM.0b013e3283212eb619262209 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
